A Retrospective Study of Reco Thrombectomy Stent for Intravascular Treatment of Acute Ischemic Stroke
NCT ID: NCT05166733
Last Updated: 2021-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2021-12-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The clinical diagnosis was acute ischemic stroke
* Large vascular lesions were detected by head CT, CTA, MRI, MRA or DSA
* Preoperative baseline NIHSS score \> 4
* MRS 0-1 before this stroke
* Mechanical thrombectomy was performed
* Use Reco thrombectomy bracket
Exclusion Criteria
* Sudden coma
* Neurological loss symptoms quickly improved
* Imaging was negative, but clinical symptoms did not rule out subarachnoid hemorrhage
* Previous intracranial hemorrhage, subarachnoid hemorrhage, and brain tumor (with mass effect)
* History of head trauma within 3 months prior to surgery
* History of arterial puncture with difficulty in compression and hemostasis within one week prior to surgery
* Physical examination revealed evidence of active bleeding or trauma (e.g. fracture)
* Women are known to be pregnant or breastfeeding
* Severe allergies to contrast agents are known
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jingjiang People's Hospital
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
The Second Hospital of Nanjing Medical University
OTHER
Northern Jiangsu People's Hospital
OTHER
Yixing People's Hospital
OTHER
PengYa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PengYa
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First People's Hospital of Changzhou
Changzhou, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jie Cao
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021（ke）CL274
Identifier Type: -
Identifier Source: org_study_id